结直肠癌（CRC）是最常见的恶性肿瘤之一，约占全球癌症发病率和死亡率的10％。约20％的CRC患者在诊断时出现转移性疾病（mCRC）。此外，高达50％的局部疾病患者最终会发生转移。mCRC涉及多种因素和过程的复杂级联反应，导致多样化的分子机制。对癌细胞发展和增殖底层路径的进一步理解，加上相关靶向药物的可及性，推动了CRC治疗的进展，最终导致了提高的生存率。 CRC中不同通路的突变和原发肿瘤的位置会影响靶向药物的疗效。本综述总结了不同CRC通路可用的靶向药物，并重点介绍了抗血管生成和抗表皮生长因子受体药物、BRAF突变以及人表皮生长因子受体2相关的靶向药物的最新进展。 版权所有©2023黄、叶、高、黄、黄、陆、卢、李、罗、谢、林和梁。

Colorectal cancer (CRC) is one of the most common malignancies, accounting for approximately 10% of global cancer incidence and mortality. Approximately 20% of patients with CRC present metastatic disease (mCRC) at the time of diagnosis. Moreover, up to 50% of patients with localized disease eventually metastasize. mCRC encompasses a complex cascade of reactions involving multiple factors and processes, leading to a diverse array of molecular mechanisms. Improved comprehension of the pathways underlying cancer cell development and proliferation, coupled with the accessibility of relevant targeted agents, has propelled advancements in CRC treatment, ultimately leading to enhanced survival rates. Mutations in various pathways and location of the primary tumor in CRC influences the efficacy of targeted agents. This review summarizes available targeted agents for different CRC pathways, with a focus on recent advances in anti-angiogenic and anti-epidermal growth factor receptor agents, BRAF mutations, and human epidermal growth factor receptor 2-associated targeted agents.Copyright © 2023 Huang, Ye, Gao, Huang, Huang, Lu, Lu, Li, Luo, Xie, Lin and Liang.